Vadim Tsvankin1, Rintaro Hashizume2, Hiroaki Katagi2, James E Herndon3, Christopher Lascola4, Talaignair N Venkatraman4, Daniel Picard5,6, Brainard Burrus7, Oren J Becher8,9, Eric M Thompson1,10. 1. Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina. 2. Department of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 3. Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina. 4. Department of Radiology, Duke University Medical Center, Durham, North Carolina. 5. Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany. 6. Department of Pediatric Neuro-Oncogenomics, German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany. 7. University of North Carolina School of Medicine, Chapel Hill, North Carolina. 8. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 9. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois. 10. Duke University Preston Robert Tisch Brain Tumor Center, Durham, North Carolina.
Abstract
BACKGROUND: An impermeable blood-brain barrier and drug efflux via ATP-binding cassette (ABC) transporters such as p-glycoprotein may contribute to underwhelming efficacy of peripherally delivered agents to treat diffuse intrinsic pontine glioma (DIPG). OBJECTIVE: To explore the pharmacological augmentation of convection-enhanced delivery (CED) infusate for DIPG. METHODS: The efficacy of CED dasatinib, a tyrosine kinase inhibitor, in a transgenic H3.3K27M mutant murine model was assessed. mRNA expression of ABCB1 (p-glycoprotein) was analyzed in 14 tumor types in 274 children. In Vitro viability studies of dasatinib, the p-glycoprotein inhibitor, tariquidar, and dexamethasone were performed in 2 H3.3K27M mutant cell lines. Magnetic resonance imaging (MRI) was used to evaluate CED infusate (gadolinium/dasatinib) distribution in animals pretreated with tariquidar and dexamethasone. Histological assessment of apoptosis was performed. RESULTS: Continuous delivery CED dasatinib improved median overall survival (OS) of animals harboring DIPG in comparison to vehicle (39.5 and 28.5 d, respectively; P = .0139). Mean ABCB1 expression was highest in K27M gliomas. In Vitro, the addition of tariquidar and dexamethasone further enhanced the efficacy of dasatinib (P < .001). In Vivo, MRI demonstrated no difference in infusion dispersion between animals pretreated with dexamethasone plus tariquidar prior to CED dasatinib compared to the CED dasatinib. However, tumor apoptosis was the highest in the pretreatment group (P < .001). Correspondingly, median OS was longer in the pretreatment group (49 d) than the dasatinib alone group (39 d) and no treatment controls (31.5 d, P = .0305). CONCLUSION: ABC transporter inhibition plus dexamethasone enhances the efficacy of CED dasatinib, resulting in enhanced tumor cellular apoptosis and improved survival in H3.3K27M mutant DIPG.
BACKGROUND: An impermeable blood-brain barrier and drug efflux via ATP-binding cassette (ABC) transporters such as p-glycoprotein may contribute to underwhelming efficacy of peripherally delivered agents to treat diffuse intrinsic pontine glioma (DIPG). OBJECTIVE: To explore the pharmacological augmentation of convection-enhanced delivery (CED) infusate for DIPG. METHODS: The efficacy of CED dasatinib, a tyrosine kinase inhibitor, in a transgenic H3.3K27M mutant murine model was assessed. mRNA expression of ABCB1 (p-glycoprotein) was analyzed in 14 tumor types in 274 children. In Vitro viability studies of dasatinib, the p-glycoprotein inhibitor, tariquidar, and dexamethasone were performed in 2 H3.3K27M mutant cell lines. Magnetic resonance imaging (MRI) was used to evaluate CED infusate (gadolinium/dasatinib) distribution in animals pretreated with tariquidar and dexamethasone. Histological assessment of apoptosis was performed. RESULTS: Continuous delivery CED dasatinib improved median overall survival (OS) of animals harboring DIPG in comparison to vehicle (39.5 and 28.5 d, respectively; P = .0139). Mean ABCB1 expression was highest in K27Mgliomas. In Vitro, the addition of tariquidar and dexamethasone further enhanced the efficacy of dasatinib (P < .001). In Vivo, MRI demonstrated no difference in infusion dispersion between animals pretreated with dexamethasone plus tariquidar prior to CED dasatinib compared to the CED dasatinib. However, tumor apoptosis was the highest in the pretreatment group (P < .001). Correspondingly, median OS was longer in the pretreatment group (49 d) than the dasatinib alone group (39 d) and no treatment controls (31.5 d, P = .0305). CONCLUSION: ABC transporter inhibition plus dexamethasone enhances the efficacy of CED dasatinib, resulting in enhanced tumor cellular apoptosis and improved survival in H3.3K27M mutant DIPG.
Authors: Ergys Subashi; Francisco J Cordero; Kyle G Halvorson; Yi Qi; John C Nouls; Oren J Becher; G Allan Johnson Journal: J Neurooncol Date: 2015-10-28 Impact factor: 4.130
Authors: Oren J Becher; Dolores Hambardzumyan; Elena I Fomchenko; Hiroyuki Momota; Lori Mainwaring; Anne-Marie Bleau; Amanda M Katz; Mark Edgar; Anna M Kenney; Carlos Cordon-Cardo; Ron G Blasberg; Eric C Holland Journal: Cancer Res Date: 2008-04-01 Impact factor: 12.701
Authors: Yilin Zhang; Shravan Kumar Sriraman; Hilary A Kenny; Ed Luther; Vladimir Torchilin; Ernst Lengyel Journal: Mol Cancer Ther Date: 2016-07-27 Impact factor: 6.261
Authors: Stephen Harward; S Harrison Farber; Michael Malinzak; Oren Becher; Eric M Thompson Journal: Childs Nerv Syst Date: 2017-11-18 Impact factor: 1.475
Authors: Alberto Broniscer; Sharyn D Baker; Cynthia Wetmore; Atmaram S Pai Panandiker; Jie Huang; Andrew M Davidoff; Arzu Onar-Thomas; John C Panetta; Thomas K Chin; Thomas E Merchant; Justin N Baker; Sue C Kaste; Amar Gajjar; Clinton F Stewart Journal: Clin Cancer Res Date: 2013-03-27 Impact factor: 12.531
Authors: Pawel Buczkowicz; Christine Hoeman; Patricia Rakopoulos; Sanja Pajovic; Louis Letourneau; Misko Dzamba; Andrew Morrison; Peter Lewis; Eric Bouffet; Ute Bartels; Jennifer Zuccaro; Sameer Agnihotri; Scott Ryall; Mark Barszczyk; Yevgen Chornenkyy; Mathieu Bourgey; Guillaume Bourque; Alexandre Montpetit; Francisco Cordero; Pedro Castelo-Branco; Joshua Mangerel; Uri Tabori; King Ching Ho; Annie Huang; Kathryn R Taylor; Alan Mackay; Anne E Bendel; Javad Nazarian; Jason R Fangusaro; Matthias A Karajannis; David Zagzag; Nicholas K Foreman; Andrew Donson; Julia V Hegert; Amy Smith; Jennifer Chan; Lucy Lafay-Cousin; Sandra Dunn; Juliette Hukin; Chris Dunham; Katrin Scheinemann; Jean Michaud; Shayna Zelcer; David Ramsay; Jason Cain; Cameron Brennan; Mark M Souweidane; Chris Jones; C David Allis; Michael Brudno; Oren Becher; Cynthia Hawkins Journal: Nat Genet Date: 2014-04-06 Impact factor: 38.330
Authors: Julian S Rechberger; Erica A Power; Victor M Lu; Liang Zhang; Jann N Sarkaria; David J Daniels Journal: Neurosurg Focus Date: 2020-01-01 Impact factor: 4.047
Authors: Marc Thomas Schönholzer; Jessica Migliavacca; Elena Alvarez; Karthiga Santhana Kumar; Anuja Neve; Alexandre Gries; Min Ma; Michael A Grotzer; Martin Baumgartner Journal: Neoplasia Date: 2020-08-17 Impact factor: 5.715